6月10日，国家药品监督管理局（NMPA）官网显示正式受理了和誉医药自主研发的CSF-1R抑制剂匹米替尼的新药上市申请（NDA），用于治疗成人腱鞘巨细胞瘤（TGCT）患者。对于成立仅9年的和誉医药（02256.HK），这是其首个进入NDA审批流程的自主研发项目，标志着公司发展进入全新阶段，董事长兼CEO徐耀昌博士称之为“和誉医药发展历程中的重大里程碑时刻”。腱鞘巨细胞瘤（TGCT）是一种局部浸润性...
Source Link6月10日，国家药品监督管理局（NMPA）官网显示正式受理了和誉医药自主研发的CSF-1R抑制剂匹米替尼的新药上市申请（NDA），用于治疗成人腱鞘巨细胞瘤（TGCT）患者。对于成立仅9年的和誉医药（02256.HK），这是其首个进入NDA审批流程的自主研发项目，标志着公司发展进入全新阶段，董事长兼CEO徐耀昌博士称之为“和誉医药发展历程中的重大里程碑时刻”。腱鞘巨细胞瘤（TGCT）是一种局部浸润性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.